Source 1review2025MED
Toolkit/high-throughput drug screening using hPSC-derived cellular models
high-throughput drug screening using hPSC-derived cellular models
Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
In the context of pharmaceutical research, hPSC-derived cellular models now underpin high-throughput drug screening and mechanistic toxicological assays, offering superior human relevance compared to traditional animal models.
Usefulness & Problems
Why this is useful
This assay use case applies hPSC-derived cellular models to high-throughput drug screening in pharmaceutical research. The abstract presents it as a major application area of advanced hPSC culture systems.; pharmaceutical screening; preclinical drug discovery
Source:
This assay use case applies hPSC-derived cellular models to high-throughput drug screening in pharmaceutical research. The abstract presents it as a major application area of advanced hPSC culture systems.
Source:
pharmaceutical screening
Source:
preclinical drug discovery
Problem solved
It addresses the limited human relevance of traditional animal models for preclinical screening.; limited human relevance of traditional animal models in screening
Source:
It addresses the limited human relevance of traditional animal models for preclinical screening.
Source:
limited human relevance of traditional animal models in screening
Problem links
limited human relevance of traditional animal models in screening
LiteratureIt addresses the limited human relevance of traditional animal models for preclinical screening.
Source:
It addresses the limited human relevance of traditional animal models for preclinical screening.
Published Workflows
Objective: Develop and deploy animal-free hPSC culture platforms that are reproducible, safe, scalable, and suitable for drug discovery and predictive toxicology.
Why it works: The review describes a progression from poorly defined feeder-dependent and xenogeneic systems to defined and synthetic platforms, then further integration of automation, AI, and 3D bioprocessing to improve standardization, quality control, and throughput for downstream pharmaceutical use.
replacement of feeder-dependent and xenogeneic matrices with chemically defined, xeno-free, and fully synthetic culture platformsuse of recombinant ECM proteins, synthetic peptide substrates, and polymer-based coatings to reduce biological variability and immunogenic riskdefined matrix engineeringsynthetic substrate designautomationartificial intelligence3D bioprocessing
Stages
- 1.Transition to defined animal-free culture platforms(library_design)
This stage exists to address long-standing reproducibility, safety, and translation problems associated with feeder-dependent and xenogeneic culture systems.
Selection: Adopt chemically defined, xeno-free, and fully synthetic platforms instead of feeder-dependent and xenogeneic matrices.
- 2.Deploy defined substrate technologies for scalable GMP-compatible culture(functional_characterization)
The review identifies these substrate classes as enabling scalable and GMP-oriented culture while reducing variability and immunogenic concerns.
Selection: Use recombinant extracellular matrix proteins, synthetic peptide substrates, and polymer-based coatings that enable GMP-compliant scalable hPSC culture.
- 3.Integrate process technologies for standardization and throughput(secondary_characterization)
The review presents these technologies as process-level enhancements after establishment of defined culture platforms.
Selection: Add automation, AI, and 3D bioprocessing to enhance standardization, quality control, and throughput.
- 4.Apply hPSC-derived models in screening and toxicology(confirmatory_validation)
The review frames pharmaceutical application as the downstream use case that benefits from improved culture platforms and process standardization.
Selection: Use hPSC-derived cellular models in high-throughput drug screening and mechanistic toxicological assays.
Taxonomy & Function
Primary hierarchy
Technique Branch
Method: A concrete measurement method used to characterize an engineered system.
Mechanisms
chemical perturbation screeningfunctional cellular response profiling in hpsc-derived modelsTarget processes
recombinationselectionInput: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor
It requires hPSC-derived cellular models and screening-compatible assay workflows. The abstract does not specify readouts, automation level, or cell types.; requires hPSC-derived cellular models
The abstract does not indicate that these screening models fully overcome issues such as cellular immaturity, inter-batch variability, or regulatory acceptance.; performance details, assay formats, and model maturity constraints are not specified in the abstract
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review states that hPSC-derived cellular models support high-throughput drug screening and mechanistic toxicological assays with greater human relevance than traditional animal models.
The review states that recombinant extracellular matrix proteins, synthetic peptide substrates, and polymer-based coatings have enabled GMP-compliant and scalable hPSC cultures while reducing biological variability and immunogenic risks.
The review states that integrating automation, AI, and 3D bioprocessing is intended to improve standardization, quality control, and throughput in hPSC culture systems.
Approval Evidence
1 source1 linked approval claimfirst-pass slug high-throughput-drug-screening-using-hpsc-derived-cellular-models
In the context of pharmaceutical research, hPSC-derived cellular models now underpin high-throughput drug screening and mechanistic toxicological assays, offering superior human relevance compared to traditional animal models.
Source:
application scopesupports
The review states that hPSC-derived cellular models support high-throughput drug screening and mechanistic toxicological assays with greater human relevance than traditional animal models.
Source:
Comparisons
Source-stated alternatives
The explicit comparator in the abstract is traditional animal models.
Source:
The explicit comparator in the abstract is traditional animal models.
Source-backed strengths
offers superior human relevance compared to traditional animal models
Source:
offers superior human relevance compared to traditional animal models
high-throughput drug screening using hPSC-derived cellular models and mechanistic toxicological assays using hPSC-derived cellular models address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection; same primary input modality: chemical
Compared with ProKAS
high-throughput drug screening using hPSC-derived cellular models and ProKAS address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection; same primary input modality: chemical
Compared with single-cell RNA sequencing
high-throughput drug screening using hPSC-derived cellular models and single-cell RNA sequencing address a similar problem space because they share recombination, selection.
Shared frame: same top-level item type; shared target processes: recombination, selection; same primary input modality: chemical
Relative tradeoffs: appears more independently replicated; looks easier to implement in practice.
Ranked Citations
- 1.